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a  b  s  t  r  a  c  t
Clostridium difﬁcile is the leading cause of infectious diarrhoea in hospitalized patients.
The  aim of this study was to determine the risk factors important for the development
of  hospital-acquired Clostridium difﬁcile-associated disease and clinical manifestations of
Clostridium difﬁcile-associated disease. The clinical trial group included 37 hospitalized
patients who were selected according to the inclusion criteria. A control group of 74 hospi-
talized patients was individually matched with cases based on hospital, age (within 4 years),
sex  and month of admission.
Clostridium difﬁcile-associated disease most commonly manifested as diarrhoea (56.76%)
and  colitis (32%), while in 8.11% of patients, it was diagnosed as pseudomembranous
colitis, and in one patient, it was diagnosed as fulminant colitis. Statistically signiﬁ-
cant  associations (p < 0.05) were found with the presence of chronic renal failure, chronic
obstructive pulmonary disease, cerebrovascular accident (stroke) and haemodialysis. In
this study, it was conﬁrmed that all the groups of antibiotics, except for tetracycline and
trimethoprim–sulfamethoxazole, were statistically signiﬁcant risk factors for Clostridium
difﬁcile-associated disease (p < 0.05). However, it was difﬁcult to determine the individual
role  of antibiotics in the development of Clostridium difﬁcile-associated disease. Univariate
logistic regression also found that applying antibiotic therapy, the duration of antibiotic
therapy, administration of two or more antibiotics to treat infections, administering laxa-
tives  and the total number of days spent in the hospital signiﬁcantly affected the onset of
Clostridium difﬁcile-associated disease (p < 0.05), and associations were conﬁrmed using the
multivariate model for the application of antibiotic therapy (p = 0.001), duration of antibiotic
treatment (p = 0.01), use of laxatives (p = 0.01) and total number of days spent in the hospital
(p  = 0.001). In this study of patients with hospital-acquired diarrhoea, several risk factors for
the  development of Clostridium difﬁcile-associated disease were identiﬁed.©  2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This isan  open access arti
∗ Correspondence to: The Faculty of Medicine in Nis, Institute for Publ
Nis,  Serbia.
http://dx.doi.org/10.1016/j.bjm.2016.07.011
1517-8382/© 2016 Sociedade Brasileira de Microbiologia. Published by 
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)cle under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
ic Health Nis, Center of Microbiology, Zorana Djindjica 50, 18000
Elsevier Editora Ltda. This is an open access article under the CC
.













































6b r a z i l i a n j o u r n a l o f m i c 
ntroduction
lostridium difﬁcile is the leading cause of infectious diarrhoea
n hospitalized patients.1 The clinical manifestations of C.
ifﬁcile-associated disease (CDAD) range from asymptomatic
olonization, mild diarrhoea, colitis, and life-threatening
seudomembranous colitis (PMC) to toxic megacolon, sepsis
nd death.2 These infections lead to prolonged hospitaliza-
ions, increased morbidity and mortality, and high health care
osts. Diseases caused by this bacterial species are an increas-
ng clinical challenge because of the emergence of resistant
trains to metronidazole.3 Previous studies have suggested
hat administration of antibiotics, old age, multiple co-morbid
onditions, previous hospitalizations, long stays in hospitals
facilities), and medical and surgical procedures are risk fac-
ors for developing the disease (CDAD).1,3,4 Some studies have
ndicated that administration of ﬂuoroquinolones and pro-
on pump inhibitors contribute to the emergence of CDAD.5
isruption of the protective role as a barrier of the normal
ntestinal ﬂora is common to many  of these factors.
bjective
he aim of this study was to determine the risk factors impor-
ant for the development of hospital-acquired CDAD and its
linical manifestations.
aterials  and  methods
he study (a prospective, case–control study) was performed
t the Institute of Public Health of the Nis, Serbia, Centre for
icrobiology from January 2013 to June 2014.
The clinical trial group included 37 hospitalized patients
Clinical Centre of Nis, Serbia) with diagnoses and only one
pisode of CDAD. The selection of patients was based on the
ollowing criteria:
 Presence of at least three unformed or liquid stools over 24 h
for at least 2 days.
 Hospitalization for at least 48 h before the appearance of
unformed or liquid stools.
 Cultivation of toxigenic strains of C. difﬁcile from examined
stool samples.
 A stool sample positive for C. difﬁcile toxins.
The control group consisted of 74 hospitalized patients
ith diarrhoea, whose stool specimens were negative for C.
ifﬁcile and toxins A/B. The patients in the control group were
ospitalized for at least 48 h in the clinics of the Clinical Cen-
re in Nis. The control patients were individually matched with
ases based on hospital, age (within 4 years), sex and month
f admission.
In this prospective study, we processed data from the clin-
cal trial and control group patients. Data were collected from
he microbiological laboratories (type of isolated microor-
anism, production of toxins) and from the clinics of the
linical Centre of Nis (sex, age, therapy applied during the
0 days before diarrhoea and its duration), including theo l o g y 4 7 (2 0 1 6) 902–910 903
following data: antibiotics, cytostatics, corticosteroids, X-ray
therapy, non-steroidal anti-inﬂammatory drugs, angiotensin-
converting enzyme (ACE) inhibitors, beta-blockers, proton
pump inhibitors, histamine 2 receptor antagonists, anticoag-
ulants, laxatives, calcium channel blockers, antiarrhythmics,
diuretics, oral drugs for diabetes, and invasive gastrointesti-
nal procedures applied in the previous 3 months (colonoscopy,
gastroscopy, nasogastric tube, enemas), the number of visits
and total time spent in the hospital before the occurrence of
CDAD, stay in the intensive care unit, underlying morbidi-
ties, and surgery in the previous 3 months. The laboratory
data were collected from the day when stool was sent for
C. difﬁcile testing (white blood cell [WBC] count >20,000/L,
serum glucose level >150 mg/dL, creatinine level >2 mg/dL,
alanine aminotransferase [ALT] levels >40 IU,  serum albumin
level <2.5 g/dL).
Daily lab reports (lab lists and protocols) about the isola-
tion of pathogens in microbiological laboratories and medical
documentation (histories of diseases, temperature lists) were
used as source data.
Standard microbiological procedures were applied dur-
ing bacteriological examinations of stool samples. Stool
samples were inoculated on nutrient selective media and
cycloserine–cefoxitin–fructose agar (CCFA) (Biomedics, Parg qe
tehnicologico, Madrid, Spain) for C. difﬁcile cultivation after
alcohol-shock procedure application.
CCF agar was incubated at 37 ◦C under anaerobic condi-
tions for 48 h. AnaeroGen sachets (AnaeroGen, OXOID, United
Kingdom) were used to create anaerobic condition in jars.
Anaerobic strips (Anaerobic indicator, OXOID, United King-
dom) were used to verify anaerobic conditions. A commercial
API system for anaerobic bacteria (API 20A BioMerieux, France)
was applied for the biochemical identiﬁcation of C. difﬁcile
isolates (typical colonies were 4 mm or larger in diameter, ele-
vated, and convex, with a discrete margin, an irregular surface
and a strong horse manure-like odour).
C. difﬁcile toxins A and B were detected in stool spec-
imens by the MINIVIDAS Clostridium difﬁcile Toxin A/B test
(BioMerieux, France). C. difﬁcile toxin A was detected in stool
specimens by the ColorPAC Toxin A test (Becton Dickinson,
USA). Colonies of C. difﬁcile were subcultivated in 5 mL  of brain-
heart infusion broth under anaerobic conditions over four
days. After incubation, liquid cultures of C. difﬁcile were cen-
trifuged at 3000 × g for 15 min. Determination of toxins was
performed using previously cited tests according to the man-
ufacturer’s instruction. The same procedure was applied to
the liquid cultures of reference strains C. difﬁcile ATCC 43598
(A−/B+) and C. difﬁcile ATCC 43255 (A+/B+), cultivated in brain-
heart infusion broth under anaerobic conditions within four
days.
The diagnosis of CDAD was based on the presence of the
following criteria6:
• Diarrhoeal stools or toxic megacolon and a positive labo-
ratory assay for C. difﬁcile toxin A and/or toxin B in stools
a toxin-producing C. difﬁcile detected in stool via culture or
other means.
Clinical manifestations of CDAD were deﬁned as recom-
mended by Kuijper et al.6
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Production of certain toxins of C. difﬁcile isolates Numbers of patients





Diarrhoea without colitis 21 (100) 0 21 56.7
Colitis 11 (91.6) 1 (8.3) 12 32.4
Pseudomembranous colitis 3 (100) 0 3 8.1
Fulminant colitis 1 (100) 0 1 2.7
Toxic megacolon 0 
Total 36 (97.3) 
The SPSS (version 15) statistical package was used for the
statistical analysis. The chi-square test (or Fisher’s exact test
as appropriate) and the t-test were used to compare demo-
graphics, co-morbid conditions, and antibiotic use between
the cases and controls. Logistic regression models were used
to identify patient-related risks. Variables found to be statis-
tically signiﬁcant by a univariate analysis were then entered
into a multivariate logistic regression analysis to identify inde-
pendent risk factors for the development of CDAD. A p-value
<0.05 was deﬁned as signiﬁcant.
Results
Data were collected for the 37 patients with CDAD, and the
data were compared with those for the 74 patients without
CDAD. The sex ratios (M/F) for the case/control patients were
20/17 and 40/34, respectively. CDAD most commonly mani-
fested clinically as diarrhoea without colitis (56.7%). There was
only one case of fulminant colitis, which had a fatal outcome
(Table 1). The MINIVIDAS C. difﬁcile Toxin A/B test was positive
for the presence of toxins in the stool samples of 37 patients
Table 2 – Underlying diseases and conditions of hospitalized pa
group.
Underlying disease Patients wit
n 
Hypertension 10 
Diabetes mellitus 6 
Malignancy 4 
Chronic obstructive pulmonary disease 5 
Chronic renal failure 8 
Haemodialysis 7 
Peritoneal dialysis 1 
Stroke, cerebrovascular accident 10 
Schizophrenia 2 






Built-in AV artiﬁcial valve 1 
Absolute arrhythmia 1 
Chronic cellulitis 1 0 0 0
1 (2.7) 37 100
with diarrhoea. The ColorPAC Toxin A test was positive for
toxin A in the stool samples of one patients with diarrhoea.
The isolates of 36 patients with diarrhoea were positive for tox-
ins A and B (A+/B+). The isolates of one patient were positive
for only toxin B (A−/B+) (Table 1).
Based on the collected data, the primary diseases that were
most prevalent among hospitalized patients with CDAD were
hypertension, diabetes, chronic renal failure and cerebrovas-
cular accident (stroke). In the majority of patients (54.0%),
there was a presence of two or more  primary diseases. The
presence of chronic renal failure, chronic obstructive pul-
monary disease and cerebrovascular accident (stroke) were
signiﬁcantly different, p < 0.05. The presence of haemodialysis
was statistically signiﬁcant (Table 2).
Univariate logistic regression in hospitalized patients
identiﬁed the following signiﬁcant risk factors for CDAD:
applied antibiotic therapy (OR = 30.13, 95% C.I.: 7.87–115.36,
p = 0.0001); duration of antibiotic therapy (OR = 6.1, 95% C.I.:
1.6–23, p = 0.001); administration of two or more  antibi-
otics in the treatment of infections (OR = 2.97, 95% C.I.:
1.19–3.04, p = 0.015); administration of laxatives (OR = 2.38,
95% C.I.: 1.39–4.06, p = 0.001); and the total number of days
tients with CDAD and hospitalized patients in the control
h CDAD (N = 37) Patients in the control group (N = 74) p
% n %
27.0 24 32.4 0.56
16.2 13 17.5 0.85
10.8 4 5.4 0.30
24.3 2 2.7 0.04
21.6 2 2.7 0.002
18.9 2 2.7 0.006
2.3 0 0 0.33
27.0 8 10.8 0.029
5.4 4 5.4 0.65
16.2 12 16.2 0.95
2.3 2 2.7 1.0
2.3 2 2.7 1.0
2.3 0 0 0.33
2.3 0 0 0.33
2.3 0 0 0.33
2.3 0 0 0.33
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Table 3 – Univariate analysis of risk factors monitored in patients.







OR  95 C.I. p
Sex, M/F 20/17 40/34 1.00 0.70–1.44 0.83
Age (years old) 63.4 ± 17.5 64.1 ± 16 1.03 1.00–1.05 0.64
Treatment
Antibiotics 34 (91.8) 19 (25.6) 30.13 7.87–115.36 0.0001
Duration of antibiotic therapy (each day for the
duration)
21  ± 5.5 12 ± 4 6.1 1.6–23 0.001
Two or more antibiotics 20 (54.0) 21 (28.3) 2.97 1.19–3.04 0.015
X-ray 1 (2.7) 1  (1.3) 2.03 0.13–31.09 0.80
Chemotherapy 2 (5.4) 3 (4.0) 1.35 0.23–7.64 0.87
Steroid treatment 4 (10.8) 9 (12.6) 0.96 0.32–2.92 0.61
Non-steroidal anti-inﬂammatory drugs 7 (18.9) 10 (13.5) 1.40 0.58–3.38 0.45
Angiotensin-converting enzyme (ACE) inhibitors 8 (21.6) 13 (17.5) 1.23 0.56–2.70 0.60
Beta blockers 6 (16.2) 19 (25.6) 0.84 0.41–1.74 0.64
Anticoagulants 7 (18.9) 13 (17.5) 1.08 0.47–2.47 0.86
Laxatives 19 (51.3) 16 (21.6) 2.38 1.39–4.06 0.001
Calcium channel blockers 4 (10.8) 4 (5.4) 2.0 0.53–7.55 0.43
Antiarrhythmics 5 (13.5) 9 (12.6) 1.16 0.42–3.21 0.49
Diuretics 6 (16.2) 8 (10.8) 1.56 0.58–4.17 0.56
Diabetes mellitus drugs 10 (27.0) 14 (18.9) 1.43 0.70–2.90 0.46
Proton pump inhibitors 8 (21.6) 9 (12.6) 1.99 0.75–4.23 0.30
Histamine 2 receptor antagonists 13 (35.1) 15 (20.2) 2.13 0.92–3.25 0.14
Medical interventions
Colonoscopy 6 (16.2) 11 (29.7) 1.11 0.44–2.72 0.92
Gastroscopy 4 (10.8) 10 (13.5) 0.78 0.27–2.38 0.47
Nasogastric tube 7 (18.9) 7 (9.4) 2.0 0.76–5.28 0.26
Surgery 10 (27.0) 12 (16.2) 1.67 0.79–3.50 0.27
Enema 11 (29.7) 13 (17.5) 1.99 0.84–3.41 0.22
Hospitalization
Stay in the intensive care unit 21 (56.7) 28 (37.8) 2.16 1.0–2.25 0.059
Number of hospital stays 5  ± 1 3  ± 0.5 1.46 0.91–2.33 0.11
Total number of days spent in the hospital 64 ± 15 29 ± 10 1.54 1.31–1.  82 0.001
Laboratory data
White blood cell (WBC) count >20,000/L  17 (45.9) 21 (28.3) 2.15 0.98–2.68 0.067
Glucose level >150 mg/dL 5 (13.5) 9 (12.6) 1.13 0.40–3.08 0.84
Creatinine >2 mg/dL 4 (10.8) 2 (2.7) 4.36 0.77–20.85 0.18
10 (13.5) 1.49 0.58–3.38 0.45


















Table 4 – Multivariate analysis of risk factors for
hospitalized patients.
Variable OR 95 C.I. p
Antibiotics 160.60 7.34–359.87 0.001
Duration of antibiotic
therapy (each day for the
duration)
1.4 1.50–2.43 0.01
Two or more antibiotics 2.2 0.8–5.9 0.099
Laxatives 1.58 1.09–3.23 0.01
The total number of days 1.14 1.06–1.23 0.001Alanine aminotransferase (ALT) >40 IU 7 (18.9) 
Albumin <2.5 g/dL 18 (48.6) 
pent in the hospital (OR = 1.54, 95% C.I.: 1.31–1.82, p = 0.001)
Table 3).
Factors analyzed by univariate logistic regression were
ntroduced into the multivariate model with adjustment for all
he analyzed parameters. Statistically signiﬁcant risk factors
or the risk of CDAD included the following: applied antibiotic
herapy (OR = 160.60, 95% C.I.: 7.34–359.87, p = 0.001); duration
f antibiotic therapy (OR = 1.4, 95% C.I.: 1.50–2.43, p = 0.01); lax-
tives (OR = 1.58, 95% C.I.: 1.09–3.23, p = 0.01); and total number
f days spent in the hospital (OR = 1.14, 95% C.I.: 1.06–1.23,
 = 0.001) (Table 4).
In the treatment of infections in hospitalized patients,
he most commonly used antibiotics were from the groups
f cephalosporins, quinolones, penicillins and aminoglyco-
ides. In addition to the tetracycline group antibiotics and
rimethoprim–sulfamethoxazole, there was a statistically sig-
iﬁcant difference for all the other groups of antibiotics
ompared to the control group of hospitalized patients
p < 0.05) (Table 5). Statistical analysis of the main data onspent in the hospital
individual antibiotics administered to hospitalized patients
found that ciproﬂoxacin, ceftriaxone, gentamicin, clin-
damycin and erythromycin were factors associated with
a high risk of developing CDAD (p < 0.01). Additionally,
other antibiotics (0.01 ≤ p < 0.05) including imipenem, van-
comycin administered orally and intravenously, cefuroxime,
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Table 5 – Representation and statistical comparison of groups of and certain individual antibiotics administered to
hospitalized patients with CDAD and hospitalized patients from the control group.
Group of antibiotics
Type of antibiotic
Patients  with CDAD (n = 37) Patients in the control group (n = 74) p
n % n %
Quinolones 21 56.7 14 18.9 <0.001
Ciproﬂoxacin 21 56.7 14 18.9 <0.001
Cephalosporins 25 62.1 17 29.9 <0.001
Ceftriaxone 11 29.7 7 9.4 <0.001
Cefuroxime 6 16.2 2 2.7 0.016
Cefepime 2 5.4 2 2.7 0.59
Ceftazidime 4 10.8 1 1.3 0.04
Cefotaxime 2 5.4 5 6.7 0.78
Penicillins 13 32.7 11 14.8 0.02
Penicillin 5 13.5 8 10.8 0.76
Ampicillin 2 5.4 1 1.3 0.25
Amoxicillin 1 2.7 1 1.3 0.55
Amoxicillin with clavulanic acid 3 8.1 0 0 0.035
Piperacillin 1 2.7 1 1.3 0.55
Piperacillin–tazobactam 1 2.7 0 0 0.33
Aminoglycosides 12 32.4 10 13.5 0.03
Gentamicin 6 16.2 1 1.3 0.005
Streptomycin 1 2.7 4 5.4 1.0
Amikacin 5 13.5 5 8.1 0.21
Carbapenems 6 16.2 1 1.3 0.005
Meropenem 2 5.4 1 1.3 0.25
Imipenem 4 10.8 0 0 0.011
Clindamycin 9 24.3 3 4.0 0.002
Vancomycin 9 24.3 2 2.7 0.0007
Vancomycin IV 6 16.2 2 2.7 0.016
Vancomycin per os 3 8.1 0 0 0.035
Macrolides 8 21.6 5 6.7 0.047
Erythromycin 6 16.2 1 1.3 0.005
Azithromycin 1 2.7 1 1.3 0.55
Roxithromycin 1 2.7 3 4.0 1.0
Trimethoprim/sulfamethoxazole 5 13.5 7 9.4 0.74
Tetracyclines 2 5.4 3 4.0 0.54
2.7 
2.7 Doxycycline 1 
Tetracycline 1 
ceftazidime, and amoxicillin with clavulanic acid, were found
to be signiﬁcant risk factors (Table 5).
Discussion
The mechanisms of settlement, maintenance and transmis-
sion of toxigenic strains of C. difﬁcile are complex and not
fully understood. Epidemiological studies have suggested that
strains of C. difﬁcile are maintained in the intestinal tracts of
humans and in hospitals. Carriers of C. difﬁcile include up to
80% of healthy children, 3% of healthy adult individuals in out-
patient conditions, and up to 20% of hospitalized patients with
formed stools. Carriers of toxigenic strains are less frequent
(0.2–0.9% of healthy adult humans) so that the colonization
of spores already present in the digestive tract is relatively
rare.7 The most likely means of the development of CDAD in
hospitalized patients is the input of spores, which can persist
for months in hospital environments and present a constant
threat for the emergence of CDAD. Spores in hospitals appear2 2.7 1.0
1 1.3 0.55
from the digestive tracts of patients with asymptomatic car-
rier states and patients with CDAD, and they can persist for
several months on a variety of surfaces and objects (ﬂoors,
furniture, medical equipment, etc.).8 Despite regular cleaning,
hospital rooms showed an 8% contamination rate for sam-
ples of C. difﬁcile spores, with contamination being higher in
rooms of patients with manifest CDAD than in the rooms of
asymptomatic carriers (49 and 29%).9
Both the spores and the vegetative forms of C. difﬁcile are
usually transmitted from contaminated surfaces and objects
to patients by the dirty hands of medical personnel.10 Transfer
of spores is facilitated by their resistance to most disinfec-
tants and antiseptics used. Some studies have indicated that
direct entry of C. difﬁcile into the intestinal tract is also possible
through contaminated objects (e.g., thermometers).11 Once C.
difﬁcile appears in health facilities, it is easily spread and main-
tained, so that in certain areas, the same strains are found, but
there have been studies showing that invasion by new strains
from the outside environment is also possible.12
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The primary requirement for the expression of the
athogenicity of toxigenic strains of C. difﬁcile is a change
n the normal relations of the bacteria colonizing the diges-
ive tract, which constitute a barrier to the proliferation of
athogenic microorganisms. More  than 90% of infections
aused by C. difﬁcile occur upon the administration of antibi-
tics. The effects of antibiotics disrupt the normal ﬂora of the
olon, allowing endogenous and exogenous microorganisms
C. difﬁcile)  to proliferate and colonize the colon.2
The presence of C. difﬁcile in the intestinal tract leads to
 number of different conditions, however, occasionally this
ype of bacteria does not cause any problems (such as asymp-
omatic colonization), but in patients with risk factors, it can
ead to diarrhoea of varying severity, including life-threatening
MC, fulminant colitis and toxic megacolon. Severe forms of
DAD (PMC, fulminant colitis, toxic megacolon, etc.) usually
ccur in 3–5% of patients with manifest C. difﬁcile infection.12
he most common clinical manifestation of CDAD in children
s watery stool, but in 26% of children, blood can also appear
n the stool. In one third of children, the disease can go into
pontaneous remission, and the mortality rate is signiﬁcantly
ower than in adults. As in adults, CDAD in children can have a
evere course, such as PMC  and necrotizing enterocolitis, but
hese courses have occurred only in sporadic cases.13,14 CDAD
sually manifests as diarrhoea in 60% of elderly patients for
pproximately ten days, while 32% of cases have been reported
s prolonged illness (up to 18 days). Severe colitis with com-
lications develops in 8% of patients.15
A study by Al-Eidan et al.,16 showed that the clinical
anifestations of CDAD in most of hospitalized patients
ncluded diarrhoea, fever, abdominal pain, and leucocyto-
is. In eight patients, the diagnosis of PMC was conﬁrmed
y endoscopic examination, and nine patients with CDAD
ied during hospitalization. The results of research by Kyne
t al.17 showed that toxigenic C. difﬁcile isolates were cul-
ured from samples of 87 patients, but CDAD did not develop
n 14 patients (asymptomatic carriers). In 24% of 73 patients
ith CDAD, mild diarrhoea was present, 35.6% had a severe
orm of diarrhoea, and 39.7% had extended symptoms and
ore severe forms of CDAD. Six patients with prolonged diar-
hoea had complications such as fulminant colitis, PMC and
oxic megacolon. Colectomy was applied in the treatment of
our patients. Three patients with colectomy died during the
ostoperative period in intensive care units, and one patient
ied within 3 weeks after surgery. The research by Changela
t al.18 found that in 5 patients, the direct cause of death
as C. difﬁcile (pseudomembranous colitis, severe colitis with
ehydration and fever, and multisystem organ damage with
epsis, and one patient had perforation of the intestines).
he clinical manifestations of CDAD in immunocompromised
atients are various, but the most commonly occurring clinical
anifestations is diarrhoea of varying severity and dura-
ion. Fulminant CDAD has been described in patients with
ung transplantation who received high doses of immuno-
uppressive corticosteroid drugs, as well as antibiotics, due
o frequent lung infections. Due to immunosuppression, the
igestive tracts of these patients do not form pseudomem-
ranes as a manifestation of CDAD.19 In this study, undertaken
n Nis, Serbia, CDAD most commonly manifested as diar-
hoea, while 8.1% of patients were diagnosed with PMC ando l o g y 4 7 (2 0 1 6) 902–910 907
2.7% of patients with fulminant colitis, which ended in death
(Table 1).
However, the validity of the results of this study should be
observed in the light of the limited sensitivity of the MINIVI-
DAS assay for diagnosis of CDAD. The sensitivity of MiniVidas
assay is 63.9–93.8%, which is less that of modern PCR tests
(98.3–100%).20 For this reason, the use of MINIVIDAS assay
as a stand-alone test is not recommended. However, in this
research, we used a two-step testing system to test C. difﬁcile
isolates. All these diagnostic methods provided validity to the
results of research and the diagnosis of CDAD.
The reasons for the different clinical manifestations
remain unknown, but the answer should probably be sought
in the possible presence of other virulence factors in some
strains of C. difﬁcile,  such as adhesion or secretion of hydrolytic
enzymes or factors that depend on human hosts. Many
researchers believe that host factors are more  important than
the virulence of the bacteria because asymptomatic children
and adult carriers can be colonized with of the same toxigenic
strain as patients with severe diarrhoea. Additionally, many
children have high levels of toxins in their faeces, without
the presence of diarrhoea or colitis. These claims have been
supported by research conﬁrming that the diseases caused by
A−/B+ C. difﬁcile could not be distinguished from the diseases
caused by A+/B+ strains of C. difﬁcile.  Previous studies have
conﬁrmed that serum antibodies and local colon antibodies
occurred in response to the presence of C. difﬁcile in 60% of
the population. Shim et al.21 indicated that asymptomatic
colonization of C. difﬁcile was associated with reduced risk of
developing CDAD. However, this protective mechanism is not
yet understood.
At the time of intestinal colonization by C. difﬁcile,  the
levels of serum IgG antibodies to toxin A were signiﬁcantly
higher in asymptomatic carriers than among persons who
developed CDAD (p < 0.001).22 Additionally, higher levels of
serum IgG antibodies to toxin B and antigens in asymptomatic
carriers were determined, but this difference was not sta-
tistically signiﬁcant. Levels of serum IgM antibodies for C.
difﬁcile were also signiﬁcantly higher in asymptomatic carri-
ers. The risk for developing CDAD is higher in patients with
C. difﬁcile colonization of the intestinal tract and low levels
of serum IgG antibodies to toxin A. The risk was signiﬁcantly
higher if the patient also suffered from a severe underlying
disease.22 Several studies have indicated that severe CDAD
forms are associated with age (>70 years old), maximum leuco-
cyte count >20,000 cells/mL, minimum albumin level <2.5 g/dL,
maximum creatine level >2 mg/dL and small bowel obstruc-
tion or ileus. Hypoalbuminaemia and elevated serum urea
levels were independently associated with mortality.23,24
According to data from previous studies, 70–90% of dis-
eases caused by C. difﬁcile develop after the administration of
antibiotics.1,3–5 The application of antibiotics in many  cases
results in the killing of the normal ﬂora of the digestive tract,
as conﬁrmed by research conducted by Bignardi25 Research by
Bartlett,26 performed in the late eighties of the last century,
showed that CDAD usually occurred after the administra-
tion of clindamycin, penicillin (extended-spectrum effect) and
cephalosporins. Analysing the results of research conducted
during the nineties, Barbut10 noted that all types of antibi-
otics, except for aminoglycosides administered intravenously,
 i c r o908  b r a z i l i a n j o u r n a l o f m
led to the appearance of at least one case of CDAD. He
also indicated that the most frequently administered antibi-
otics were lincosamine (clindamycin), extended-spectrum
penicillins and cephalosporins. Over the last ten years, the
representations of certain groups of antibiotics administered
before the occurrence of CDAD have changed. Kuijper et al.6 in
their research reported that, before the occurrence of CDAD,
patients usually received antibiotics from the cephalosporin
group (44.8% of patients), penicillin (39.8% patients), ﬂu-
oroquinolones (13.3%), aminoglycosides (10.4%), macrolides
(8.1%), carbapenems (7%), and clindamycin (8.9%). Similar
results were published by Vesta et al.4 Before the occurrence of
CDAD, antibiotics were usually administered in combinations
of two or more,  which increased the risk of developing the dis-
ease. This study also conﬁrmed that all groups of antibiotics,
except for tetracycline and trimethoprim–sulfamethoxazole
(p > 0.05), were statistically signiﬁcant risk factors for CDAD
in hospitalized patients (p < 0.05) (Table 5).
Analysing the data on certain antibiotics administered
in hospitalized patients before the occurrence of diar-
rhoea, Changela et al.18 determined the signiﬁcant risk
factors (p < 0.001) for the development of CDAD, includ-
ing imipenem, vancomycin (administered intravenously),
piperacillin–tazobactam, levoﬂoxacin, ceftriaxone, cef-
tazidime, cefepime, and clindamycin. Other antibiotics have
also been determined (p < 0.01) to be signiﬁcant risk factors
(vancomycin [administered orally], piperacillin, ciproﬂoxacin,
cefoxitin, cefuroxime, gentamycin, erythromycin and ampi-
cillin). The results of this study indicated that one risk
factor might be the application of antibiotics to which C.
difﬁcile is sensitive in vitro (e.g., vancomycin). This paradox
remains unresolved, but it is assumed that the proliferation
of C. difﬁcile from persisting spores is faster, leading to its
dominance during the renewal of the colon ﬂora.27 A more
detailed analysis of the research results18 indicated that
27% of patients received one antibiotic, while 61% received
multiple antibiotics simultaneously. Only 12% of patients
did not receive antibiotics before the occurrence of CDAD.
The study showed that antibiotics are the most important
risk factors for CDAD, primarily antibiotics from the group
of cephalosporins and penicillins, along with quinolones,
which were not available in the eighties and nineties of the
last century. The older quinolones (including ciproﬂoxacin)
had little effect on anaerobic bacteria, while moxiﬂoxacin
and gatiﬂoxacin have signiﬁcantly increased activity against
anaerobes.28,29 Considering that, in most CDAD cases, mul-
tiple antibiotics were administered simultaneously, it is not
surprising that this research determined those antibiotics
administered intravenously as risk factors; however, it is
known that in pharmacological terms, after such administra-
tion, their concentrations in the intestines are low. However, it
is difﬁcult to determine the individual role of antibiotics in the
development of CDAD. The results of research conducted in
Nis determined that the administration of certain antibiotics
in hospitalized patients had a statistically signiﬁcant inﬂu-
ence on the occurrence of CDAD (Table 5). Univariate logistic
regression also showed that applied antibiotic treatment,
duration of the therapy, and administration of two or more
antibiotics for the treatment of infections had statistically
signiﬁcant inﬂuences on the development of CDAD (Table 3), b i o l o g y 4 7 (2 0 1 6) 902–910
which was also conﬁrmed by the multivariate model for the
application of antibiotic treatment and its duration (Table 4).
The data obtained from epidemiological studies have indi-
cated that C. difﬁcile infections occur more  frequently in
patients hospitalized for more  than 8 days and in geriatric
patients hospitalized for more  than 36 days,30,31 which were
associated with prolonged exposure to C. difﬁcile.  In this study,
we also conﬁrmed that prolonged hospitalization affected the
occurrence of CDAD (Tables 3 and 4). Similar to the research
by Obritsch et al.,32 this research determined a connection
between the development of CDAD and the intake of laxa-
tives, in contrast to other studies.33 Some studies have shown
that nasogastric tubes, gastrostomy and faecal incontinence
were risk factors for CDAD.30,31 Additionally, the use of drugs
that reduce gastric acidity favour the development of CDAD. It
is assumed that the reduction in gastric acidity decreases the
killing of bacteria and facilitates the colonization of the diges-
tive tract by C. difﬁcile.  It is still not clear whether a low albumin
level is a risk factor for CDAD (it also occurs in the major-
ity of patients with severe diseases but without diarrhoea) or
whether it is the result of diarrhoea associated with the taking
of antibiotics, which also causes protein-losing enteropathy.33
In a study by Al-Eidan et al.,16 the statistically signiﬁ-
cant risk factors for CDAD were female sex, a stay in the
intensive care unit and the patient’s age. In addition to their
research, there have also been studies showing that women
more  frequently have diarrhoea during hospitalization (54%:
46%), which has also been explained by the use of antibi-
otics to treat urinary tract infections; however, in contrast to
this explanation, there have been a greater number of stud-
ies showing no statistically signiﬁcant difference in terms of
CDAD patients’ sexes.18,33
The importance of the application of oncological ther-
apy (chemotherapy, cytostatics, X-rays) as a risk factor for
the development of CDAD could not be reliably determined
because these patients often develop infections that require
antibiotics. Previous research has shown that the administra-
tion of antibiotics and cytostatics is only a risk factor for CDAD,
but there have been rare studies indicating cytostatics alone as
a risk factor.34–37 The application of antibiotics increases the
relative risk of developing CDAD in patients receiving cyto-
static chemotherapy.
The majority of studies that have examined CDAD have
shown that patient age (especially older than 60 years) is one of
the most important risk factors for the development of CDAD.
Age causes changes in the faecal ﬂora, the body’s resistance
and immunity are weakened, and a signiﬁcant number of
other risk factors are also present in the elderly, such as longer
hospitalization, several underlying and serious illnesses, and
complications during treatment.12,33 It is interesting that there
is evidence that under in vitro conditions, the faecal intesti-
nal contents of elderly patients do not inhibit the growth of C.
difﬁcile compared to younger patients.33 For all these reasons,
CDAD is common in people who are placed in nursing homes
or treated in geriatric wards and hospitals that specialize in
the care of the elderly and bedridden people.According to the results of a large number of studies,
the presence of a severe underlying disease is an important
predisposing factor for the development of CDAD in hospital-
ized patients. In a study by Al-Eidan et al.,16 all 87 of their
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ospitalized patients with CDAD had severe underlying dis-
ases (pneumonia or other respiratory tract infections – 46%,
iabetes mellitus – 42%, ischaemic heart disease – 34.5%,
ypertension – 31%, chronic obstructive diseases of the respi-
atory tract – 17%, kidney disease – 3.3%, and liver disease
 2.3%). The presence of two or more  simultaneous diseases
as found in 21 patients (24.1%). In their study, Kyne et al.38
ound that CDAD was associated with extremely severe under-
ying disease (OR = 17.6; 95% C.I. = 8.8–53.5). Diseases classiﬁed
ccording to Horn’s index as severe and very severe with
omplications were statistically strongly associated with the
evelopment of CDAD. The probability that these patients will
evelop CDAD is 27%, and if Horn’s index of the severity of
nderlying disease on admission is 1 or 2, then the probabil-
ty of developing CDAD is 4%. The study also showed that the
verage time for colonization of the intestines by C. difﬁcile
as 6 days (3–33 days), provided that the time for colonization
as the same in all groups based on Horn’s index. This ﬁnding
onﬁrmed that the severity of the disease was directly associ-
ted with CDAD. These patients also have damaged immune
esponses and weakened general immune defences, which
ould play important roles in their high sensitivity to C. difﬁ-
ile, which colonizes the digestive tract and causes diarrhoea.
he results of this research performed in Nis were consistent
ith previously published data (Table 2).
onclusion
n this study, it was found that CDAD in hospitalized patients
sually manifested as diarrhoea, but in a small number of
ases (10.8%), it occurred in more  severe forms of the disease
PMC and fulminant colitis). Additionally, several risk factors
or the development of CDAD were identiﬁed (applied antibi-
tic therapy, duration of antibiotic therapy, laxatives and total
umber of days spent in the hospital). Targeting patients with
hese risk factors for the application of preventive measures
ould reduce the incidence of and morbidity due to disease
aused by C. difﬁcile.
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